BSPM Biostar Pharmaceuticals Inc (CE)

SCHEDULE 13G

SCHEDULE 13G

SCHEDULE 13G

Page 5 of 9

Biostar Pharmaceuticals, Inc. (the “ Issuer ”)

No. 588 Shiji Avenue

Xiangyang City, Shaanxi Province, People’s Republic of China 712046

This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“ Mr. Kopin ”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“ Mr. Asher ”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“ Intracoastal ” and together with Mr. Kopin and Mr. Asher, collectively the “ Reporting Persons ”).

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1 , pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

Common stock, $0.001 par value per share, of the Issuer (the “ Common Stock ”).

090678301

Not applicable.

(a) and (b):

(i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on October 11, 2016 (the “ SPA ”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on October 12, 2016), each of the Reporting Persons may have been deemed to have beneficial ownership of 212,500 shares of Common Stock that were to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock in the aggregate represented beneficial ownership of approximately 8.7% of the Common Stock, based on (1) 2,218,188 shares of Common Stock outstanding as of October 11, 2016 as reported by the Issuer, plus (2) 212,500 shares of Common Stock that were to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 106,250 shares of Common Stock

Page 6 of 9

issuable upon exercise of a warrant that was to be issued to Intracoastal at the closing of the transactions contemplated by the SPA (“ Intracoastal Warrant 1 ”) because Intracoastal Warrant 1 is not exercisable until on or after April 16, 2017 (and Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, of more than 4.9% of the Common Stock) and (II) 56,571 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (the “ Intracoastal Warrant 2 ”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, of more than 4.9% of the Common Stock. Without such blocker provisions (and assuming Intracoastal Warrant 1 was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 375,321 shares of Common Stock.

(ii) As of the close of business on October 19, 2016, each of the Reporting Persons may be deemed to have beneficial ownership of 56,571 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock in the aggregate represented beneficial ownership of approximately 2.1% of the Common Stock, based on (1) 2,218,188 shares of Common Stock outstanding as of October 11, 2016 as reported by the Issuer, plus (2) 425,000 shares of Common Stock that were issued at the closing of the transaction contemplated by the SPA and (3) 56,571 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes 106,250 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 is not exercisable until on or after April 16, 2017 (and Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, of more than 4.9% of the Common Stock). Without such blocker provision (and assuming Intracoastal Warrant 1 was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 162,821 shares of Common Stock.

(c)

Number of shares as to which each Reporting Person has:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☑.

Not applicable.

Not applicable.

Not applicable.

Not applicable.

Page 7 of 9

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Page 8 of 9

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 19, 2016

Page 9 of 9

Exhibit 1

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date: October 19, 2016